Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Elevated chromogranin-A (CgA) levels are observed in heart failure patients, but the myocardial source and functional impact remain unclear.
• Understanding the origin and role of CgA in cardiac dysfunction is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To investigate whether the myocardium produces CgA.
• To determine the effect of CgA on myocardial function in heart failure.

Main Methods:

• Plasma CgA levels, immunohistochemistry, PCR, and ELISA were performed on myocardial biopsies from patients with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM).
• CgA fragments in plasma were analyzed using HPLC, and their effects on cardiac performance were assessed in isolated perfused rat hearts.

Main Results:

• Patients with DCM and HCM exhibited significantly increased plasma CgA levels, correlating positively with left ventricular end-diastolic pressure and plasma brain natriuretic peptide (BNP).
• Immunohistochemistry confirmed CgA expression in the myocardium of heart failure patients, co-localizing with BNP.
• CgA mRNA was detected in all myocardium samples, while significant CgA protein was found only in pathologic myocardium. Vasostatin-1, a CgA fragment, demonstrated negative inotropic and lusitropic effects in rat hearts.

Conclusions:

• Chromogranin-A (CgA) is produced by the human myocardium and exerts negative inotropic and lusitropic effects on the mammalian heart.
• CgA plays a role in the neuroendocrine regulation of cardiac function and represents a potential therapeutic target for heart failure.